Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
ProQR Therapeutics N.V. Ordinary Shares (PRQR), a clinical-stage biotech firm focused on RNA-based therapies for rare genetic diseases, is trading at $1.82 as of April 6, 2026, marking a 6.55% gain in recent trading. This analysis evaluates current price action, sector context, key technical support and resistance levels, and potential near-term scenarios for the stock, with no recent earnings data available for the company as of this publication. The recent upward move comes amid mixed sentimen
Is ProQR (PRQR) Stock Good for Short Term | Price at $1.82, Up 6.55% - Take Profit Levels
PRQR - Stock Analysis
3112 Comments
1891 Likes
1
Osei
Active Contributor
2 hours ago
I need to find others thinking the same.
👍 163
Reply
2
Vandi
Expert Member
5 hours ago
The way this turned out is simply amazing.
👍 201
Reply
3
Sapir
New Visitor
1 day ago
I don’t know what’s happening, but I’m involved now.
👍 84
Reply
4
Rashid
Experienced Member
1 day ago
Free US stock valuation models and price target projections from professional analysts covering Wall Street expectations. We help you understand fair value estimates and potential upside or downside scenarios for any stock.
👍 247
Reply
5
Joaopaulo
Experienced Member
2 days ago
I’d pay to watch you do this live. 💵
👍 165
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.